          |
|
Scott R. Naisbitt, M.D., Ph.D., Principal Scott Naisbitt is a principal of RiverVest and former Kauffman Fellow. He has experience in medical device development and a strong background in molecular biology, clinical medicine, and neuroscience. Before joining RiverVest, he was an associate of Seedling Enterprises, a medical device fund and incubator, where he evaluated potential investments and co-invented an electrosurgical instrument successfully sold to a major medical device and pharmaceutical company. At RiverVest, Dr. Naisbitt focuses on both biopharmaceutical and medical device investments. He currently serves as a board observer at CGI Pharmaceuticals and Kereos, both Fund I portfolio companies. Dr. Naisbitt has clinical and research experience at the Harvard-M.I.T. Division of Health Sciences and Technology, Massachusetts General Hospital, and Harvard Medical School. He has multiple research publications including the discovery of a physical bridge linking NMDA and metabotropic glutamate receptors, key mechanistic components of learning and memory. Dr. Naisbitt has an M.D. and Ph.D. from Harvard Medical School and the Harvard-M.I.T. Division of Health Sciences and Technology, where he was awarded an N.I.H. Medical Scientist Training Program Scholarship. He also received a B.S. in physics and mathematics from the University of Utah. Scott R. Naisbitt, M.D., Ph.D. |
©2005 RiverVest Venture Management, LLC